EFFECT OF FK506 ADMINISTRATION IN ALPHA MOTOR NEURONS AFTER PRIMARY AND DELAYED REPAIR OF THE SCIATIC NERVE

Abstract

Objectives: FK506 is an effective immunosuppressive drug for treating graft rejection in transplants patients. However, the neuroregenerative effect of FK506 has been well described in the literature. The aim of this study was to investigate the effects of FK506 in alpha motor neurons after primary and delayed repair of sciatic nerve.
Methods: Rats (n=72) were divided into 6 groups. Control, sham-operated, primary repair FK506 (-), primary repair FK506 (+), delayed repair FK506 (-), and delayed repair FK506 (+) groups.
Results: After injury, the normal structure of the motor neuron perikarya was maintained by primary repair in the FK506 (+) group. In the delayed repair group, beneficial effect of FK506 was found to be less effective. The SFI value reached -50 recovery level in the FK506-treated group earlier than those of not FK506-treated groups.
Conclusion: Beneficial effect of FK506 has been approved by functional and ultrastructural data in both of primary and delayed repair groups.

Keywords

• delayed repair
• FK506
• primary repair
• regeneration
• sciatic nerve

References

1. Aldskogius H, Kozlova EN. Central neuron-glial and glial-glial
2. interactions following axon injury. Prog Neurobiol 1998;55:1–26.
3. Bisby MA, Tetzlaff W. Changes in cytoskeletal protein synthesis following
4. axon injury and during axon regeneration. Mol Neurobiol
5. ;6:107–23.
6. de la Cruz RR, Pastor AM, Delgado-Garcia JM. Influence of the
7. postsynaptic target on the functional properties of neurons in the
8. adult mammalian central nervous system. Rev Neurosci 1996;7:115–

9. Lowrie MB, Vrbova G. Dependence of postnatal motoneurones on
10. their targets: review and hypothesis. Trends Neurosci 1992;15:80–4.
11. Hefti F. Pharmacology of neurotrophic factors. Annu Rev
12. Pharmacol Toxicol 1997;37:239–67.
13. Lindsay RM. Neurotrophins and receptors. Prog Brain Res
14. ;103:3–14.
15. Muller HW. Gene expression in nerve regeneration. Diabet Med
16. ;13:682.
17. Sendtner M. Neurotrophic factors for experimental treatment of
18. motoneuron disease. Prog Brain Res 1996;109:365–71.
19. Terenghi G. Peripheral nerve regeneration and neurotrophic factors.
20. J Anat 1999;194:1–14.
21. Snider WD, Elliott JL, Yan Q. Axotomy-induced neuronal death
22. during development. J Neurobiol 1992;23:1231–46.
23. Hoffmann CF, Choufoer H, Marani E, Thomeer RT.
24. Ultrastructural study on avulsion effects of the cat cervical motoaxonal
25. pathways in the spinal cord. Clin Neurol Neurosurg 1993;95:
26. S39–47.
27. Martin LJ, Kaiser A, Price AC. Motor neuron degeneration after sciatic
28. nerve avulsion in adult rat evolves with oxidative stress and is
29. apoptosis. J Neurobiol 1999;40:185–201.
30. Novikov L, Novikova L, Kellerth JO. Brain-derived neurotrophic
31. factor promotes survival and blocks nitric oxide synthase expression
32. in adult rat spinal motoneurons after ventral root avulsion. Neurosci
33. Lett 1995;200:45–8.
34. Wu W. Expression of nitric-oxide synthase (NOS) in injured CNS
35. neurons as shown by NADPH diaphorase histochemistry. Exp
36. Neurol 1993;120:153–9.
37. Tandrup T, Woolf CJ, Coggeshall RE. Delayed loss of small dorsal
38. root ganglion cells after transection of the rat sciatic nerve. J Comp
39. Neurol 2000;422:172–80.
40. Johnson IP, Duberley RM. Motoneuron survival and expression of
41. neuropeptides and neurotrophic factor receptors following axotomy
42. in adult and ageing rats. Neuroscience 1998;84:141–50.
43. Mattsson P, Meijer B, Svensson M. Extensive neuronal cell death
44. following intracranial transection of the facial nerve in the adult rat.
45. Brain Res Bull 1999;49:333–41.
46. Tornqvist E, Aldskogius H. Motoneuron survival is not affected by
47. the proximo-distal level of axotomy but by the possibility of regenerating
48. axons to gain access to the distal nerve stump. J Neurosci Res
49. ;39:159–65.
50. Yu WH. Regulation of nitric oxide synthase expression in motoneurons
51. following nerve injury. Dev Neurosci 1997;19:247–54.
52. Arvidsson J, Aldskogius H. Effect of repeated hypoglossal nerve
53. lesions on the number of neurons in the hypoglossal nucleus of adult
54. rats. Exp Neurol 1982;75:520–4.
55. Crews LL, Wigston DJ. The dependence of motoneurons on their
56. target muscle during postnatal development of the mouse. J
57. Neurosci 1990;10:1643–53.
58. Johnson IP, Sears TA, Hunter AS. Retrograde response to axotomy
59. of motoneurons in the thoracic spinal cord of the aging cat.
60. Neurobiol Aging 1991;12:151–60.
61. Kuzis K, Coffin JD, Eckenstein FP. Time course and age dependence
62. of motor neuron death following facial nerve crush injury: role
63. of fibroblast growth factor. Exp Neurol 1999;157:77–87.
64. Anneser JM, Berthele A, Borasio GD, Castro-Lopes JM,
65. Zieglgansberger W, Tolle TR. Axotomy of the sciatic nerve differentially
66. affects expression of metabotropic glutamate receptor
67. mRNA in adult rat motoneurons. Brain Res 2000;868:215–21.
68. Vanden Noven S, Wallace N, Muccio D, Turtz A, Pinter MJ. Adult
69. spinal motoneurons remain viable despite prolonged absence of
70. functional synaptic contact with muscle. Exp Neurol 1993;123:147–
71. Kim HS, Park YI. Isolation and identification of a novel microorganism
72. producing the immunosuppressant tacrolimus. J Biosci
73. Bioeng 2008;105:418–21.
74. Abraham RT, Wiederrecht GJ. Immunopharmacology of
75. rapamycin. Annu Rev Immunol 1996;14:483–510.
76. Dumont FJ, Ok H, Lin S, Kastner CA, Cryan J, Martin MM,
77. Wiederrecht G, Staruch MJ. Mixed agonist/antagonist activity of an
78. FK-506-related immunosuppressant: biological and biochemical
79. characterization. J Pharmacol Exp Ther 1996;276:1078–88.
80. Brenner MJ, Fox IK, Kawamura DH, Yu VM, Lowe JB 3rd, Hunter
81. DA, Mackinnon SE. Delayed nerve repair is associated with diminished
82. neuroenhancement by FK506. Laryngoscope 2004;114:570–6.
83. Costantini LC, Chaturvedi P, Armistead DM, McCaffrey PG,
84. Deacon TW, Isacson O. A novel immunophilin ligand: distinct
85. branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of
86. Parkinson's disease. Neurobiol Dis 1998;5:97–106.
87. Arii T, Kamiya T, Arii K, Ueda M, Nito C, Katsura KI, Katayama
88. Y. Neuroprotective effect of immunosuppressant FK506 in transient
89. focal ischemia in rat: therapeutic time window for FK506 in transient
90. focal ischemia. Neurol Res 2001;23:755–60.
91. Ebisu T, Katsuta K, Fujikawa A, Aoki I, Umeda M, Naruse S,
92. Tanaka C. Early and delayed neuroprotective effects of FK506 on
93. experimental focal ischemia quantitatively assessed by diffusionweighted
94. MRI. Magn Reson Imaging 2001;19:153–60.
95. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective
96. effects of FK506 in focal cerebral ischaemia. Nature 1994;371:336–9.
97. Bavetta S, Hamlyn PJ, Burnstock G, Lieberman AR, Anderson PN.
98. The effects of FK506 on dorsal column axons following spinal cord
99. injury in adult rats: neuroprotection and local regeneration. Exp
100. Neurol 1999;158:382–93.
101. Madsen JR, MacDonald P, Irwin N, Goldberg DE, Yao GL, Meiri
102. KF, Rimm IJ, Stieg PE, Benowitz LI. Tacrolimus (FK506) increases
103. neuronal expression of GAP-43 and improves functional recovery
104. after spinal cord injury in rats. Exp Neurol 1998;154:673–83.
105. Gold BG, Yew JY, Zeleny-Pooley M. The immunosuppressant
106. FK506 increases GAP-43 mRNA levels in axotomized sensory neurons.
107. Neurosci Lett 1998;241:25–8.
108. Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH.
109. Immunosuppressant FK506 promotes neurite outgrowth in cultures
110. of PC12 cells and sensory ganglia. Proc Natl Acad Sci USA
111. ;91:3191–5.
112. Gold BG, Gordon HS, Wang MS. Efficacy of delayed or discontinuous
113. FK506 administrations on nerve regeneration in the rat sciatic
114. nerve crush model: lack of evidence for a conditioning lesion-like
115. effect. Neurosci Lett 1999;267:33–6.
116. Gold BG, Katoh K, Storm-Dickerson T. The immunosuppressant
117. FK506 increases the rate of axonal regeneration in rat sciatic nerve.
118. J Neurosci 1995;15:7509–16.
119. Lee M, Doolabh VB, Mackinnon SE, Jost S. FK506 promotes functional
120. recovery in crushed rat sciatic nerve. Muscle Nerve
121. ;23:633–40.
122. Wang MS, Zeleny-Pooley M, Gold BG. Comparative dose-dependence
123. study of FK506 and cyclosporin A on the rate of axonal regeneration
124. in the rat sciatic nerve. J Pharmacol Exp Ther 1997;282:
125. –93.
126. Navarro X, Udina E, Ceballos D, Gold BG. Effects of FK506 on
127. nerve regeneration and reinnervation after graft or tube repair of
128. long nerve gaps. Muscle Nerve 2001;24:905–15.
129. Sarikcioglu L, Duygulu E, Aydin H, Gurer EI, Ozkan O, Tuzuner
130. S. Effects of intrathecal administration of FK506 after sciatic nerve
131. crush injury. J Reconstr Microsurg 2006;22:649–54.
132. Sobol JB, Lowe IJ, Yang RK, Sen SK, Hunter DA, Mackinnon SE.
133. Effects of delaying FK506 administration on neuroregeneration in a
134. rodent model. J Reconstr Microsurg 2003;19:113–8.
135. Chunasuwankul R, Ayrout C, Dereli Z, Gal A, Lanzetta M, Owen E.
136. Low dose discontinued FK506 treatment enhances peripheral nerve
137. regeneration. Int Surg 2002;87:274–8.
138. Jost SC, Doolabh VB, Mackinnon SE, Lee M, Hunter D.
139. Acceleration of peripheral nerve regeneration following FK506
140. administration. Restor Neurol Neurosci 2000;17:39–44.
141. Sulaiman OA, Midha R, Munro CA, Matsuyama T, Al-Majed A,
142. Gordon T. Chronic Schwann cell denervation and the presence of a
143. sensory nerve reduce motor axonal regeneration. Exp Neurol
144. ;176:342–54.
145. Sulaiman OA, Voda J, Gold BG, Gordon T. FK506 increases
146. peripheral nerve regeneration after chronic axotomy but not after
147. chronic schwann cell denervation. Exp Neurol 2002;175:127–37.
148. Pockett S, Gavin RM. Acceleration of peripheral nerve regeneration
149. after crush injury in rat. Neurosci Lett 1985;59:221–4.
150. Doolabh VB, Mackinnon SE. FK506 accelerates functional recovery
151. following nerve grafting in a rat model. Plast Reconstr Surg 1999;
152. :1928–36.
153. Fansa H, Keilhoff G, Altmann S, Plogmeier K, Wolf G, Schneider
154. W. The effect of the immunosuppressant FK 506 on peripheral
155. nerve regeneration following nerve grafting. J Hand Surg Br 1999;
156. :38–42.
157. Yang RK, Lowe JB, 3rd, Sobol JB, Sen SK, Hunter DA, Mackinnon
158. SE. Dose-dependent effects of FK506 on neuroregeneration in a rat
159. model. Plast Reconstr Surg 2003;112:1832–40.
160. Buttemeyer R, Rao U, Jones NF. Peripheral nerve allograft transplantation
161. with FK506: functional, histological, and immunological
162. results before and after discontinuation of immunosuppression. Ann
163. Plast Surg 1995;35:396–401.
164. Grand AG, Myckatyn TM, Mackinnon SE, Hunter DA. Axonal
165. regeneration after cold preservation of nerve allografts and immunosuppression with tacrolimus in mice. J Neurosurg 2002;96:924–32.
166. Weinzweig N, Grindel S, Gonzalez M, Kuy D, Fang J, Shahani B.
167. Peripheral-nerve allotransplantation in rats immunosuppressed with
168. transient or long-term FK-506. J Reconstr Microsurg 1996;12:451–9.
169. Bignotti B, Origo C, Schenone A, Ratto S, Mancardi GL, Ferrari
170. ML. Experimental studies on peripheral nerve repair following early
171. or delayed suture. Ital J Orthop Traumatol 1986;12:259–66.
172. Bolesta MJ, Garrett WE Jr, Ribbeck BM, Glisson RR, Seaber AV,
173. Goldner JL. Immediate and delayed neurorrhaphy in a rabbit model:
174. a functional, histologic, and biochemical comparison. J Hand Surg
175. Am 1988;13:352–7.
176. Fu SY, Gordon T. Contributing factors to poor functional recovery
177. after delayed nerve repair: prolonged denervation. J Neurosci
178. ;15:3886–95.
179. Grabb WC. Median and ulnar nerve suture. An experimental study
180. comparing primary and secondary repair in monkeys. J Bone Joint
181. Surg Am 1968;50:964–72.
182. Irintchev A, Draguhn A, Wernig A. Reinnervation and recovery of
183. mouse soleus muscle after long-term denervation. Neuroscience
184. ;39:231–43.
185. Van Beek A, Glover JL, Zook E. Primary versus delayed-primary
186. neurorrhaphy in rat sciatic nerve. J Surg Res 1975;18:335–9.
187. Wang MS, Gold BG. FK506 increases the regeneration of spinal
188. cord axons in a predegenerated peripheral nerve autograft. J Spinal
189. Cord Med 1999;22:287–96.
190. Kujawa KA, Jones KJ. Testosterone-induced acceleration of recovery
191. from facial paralysis in male hamsters: temporal requirements of
192. hormone exposure. Physiol Behav 1990;48:765–8.
193. Kujawa KA, Kinderman NB, Jones KJ. Testosterone-induced acceleration
194. of recovery from facial paralysis following crush axotomy of
195. the facial nerve in male hamsters. Exp Neurol 1989;105:80–5.
196. de Medinaceli L, Freed WJ, Wyatt RJ. An index of the functional
197. condition of rat sciatic nerve based on measurements made from
198. walking tracks. Exp Neurol 1982;77:634–43.
199. Carlton JM, Goldberg NH. Quantitating integrated muscle function
200. following reinnervation. Surg Forum 1986;37:611–2.
201. Bain JR, Mackinnon SE, Hunter DA. Functional evaluation of complete
202. sciatic, peroneal, and posterior tibial nerve lesions in the rat.
203. Plast Reconstr Surg 1989;83:129–38.
204. Fu SY, Gordon T. Contributing factors to poor functional recovery
205. after delayed nerve repair: prolonged axotomy. J Neurosci
206. ;15:3876–85.
207. Kobayashi J, Mackinnon SE, Watanabe O, Ball DJ, Gu XM, Hunter
208. DA, Kuzon WM Jr. The effect of duration of muscle denervation on
209. functional recovery in the rat model. Muscle Nerve 1997;20:858–66.
210. Totosy de Zepetnek JE, Zung HV, Erdebil S, Gordon T.
211. Innervation ratio is an important determinant of force in normal and
212. reinnervated rat tibialis anterior muscles. J Neurophysiol 1992;67:
213. –403.
214. Viguie CA, Lu DX, Huang SK, Rengen H, Carlson BM.
215. Quantitative study of the effects of long-term denervation on the
216. extensor digitorum longus muscle of the rat. Anat Rec 1997;248:
217. –54.
218. Gordon T, Fu SY. Long-term response to nerve injury. Adv Neurol
219. ;72:185–99.
220. Sulaiman OA, Gordon T. Effects of short- and long-term Schwann
221. cell denervation on peripheral nerve regeneration, myelination, and
222. size. Glia 2000;32:234–46.
223. Hizay A, Demirel BM, Gokhan G, Sarikcioglu L, Demir N. Does
224. FK506 reduce the size of the watershed area after vascular injury of
225. the sciatic nerve? Rom J Morphol Embryol 2011;52:1077–80.
226. Sarikcioglu L, Demir N, Akar Y, Demirtop A. Effect of intrathecal
227. FK506 administration on intraorbital optic nerve crush: an ultrastructural
228. study. Can J Ophthalmol 2009;44:427–30.
229. Utuk A, Sarikcioglu L, Demirel BM, Demir N. The immunosuppressive
230. agent FK506 prevents subperineurial degeneration and
231. demyelination on ultrastructural and functional analysis. Curr
232. Neurovasc Res 2009;6:252–8.
233. Yildirim FB, Sarikcioglu L, Ozsoy U, Demir N, Demirtop A, Ucar
234. Y. Effect of FK506 administration after obturator nerve injury: a
235. functional and ultrastructural study. Acta Neurobiol Exp (Wars)
236. ; 68:477–83.
237. Ma J, Novikov LN, Wiberg M, Kellerth JO. Delayed loss of spinal
238. motoneurons after peripheral nerve injury in adult rats: a quantitative
239. morphological study. Exp Brain Res 2001;139:216–23.
240. Guntinas-Lichius O, Effenberger K, Angelov DN, Klein J, Streppel
241. M, Stennert E, Neiss WF. Delayed rat facial nerve repair leads to
242. accelerated and enhanced muscle reinnervation with reduced collateral
243. axonal sprouting during a definite denervation period using a
244. cross-anastomosis paradigm. Exp Neurol 2000;162:98–111.